Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. May 27, 2023; 15(5): 906-916
Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.906
Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer
Yi-Ling Jiang, Xue-Yuan Fu, Zhi-Hui Yin
Yi-Ling Jiang, Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, Hunan Province, China
Xue-Yuan Fu, Zhi-Hui Yin, Department of Anorectal, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, Hunan Province, China
Author contributions: Jiang YL drafted the manuscript; Jiang YL and Fu XY collected and analyzed the clinical data; Yin ZH designed the study, reviewed and revised the manuscript; and all authors have read and approved the final manuscript.
Institutional review board statement: The study was approved by the Ethics Committee of The First Affiliated Hospital, Hengyang Medical School, University of South China.
Informed consent statement: The data used in this study were not involved in the patients’ private information, so the informed consent was waived by the Ethics Committee of The First Affiliated Hospital, Hengyang Medical School, University of South China. All patient data obtained, recorded and managed are only used for this study, and all patient information is strictly confidential, without any harm to the patient.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Hui Yin, MM, Associate Chief Physician, Department of Anorectal, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Avenue, Shigu District, Hengyang 421001, Hunan Province, China. yinzhihui6996@163.com
Received: February 19, 2023
Peer-review started: February 19, 2023
First decision: March 1, 2023
Revised: March 11, 2023
Accepted: April 7, 2023
Article in press: April 7, 2023
Published online: May 27, 2023
Processing time: 95 Days and 23.3 Hours
ARTICLE HIGHLIGHTS
Research background

Olaparib and bevacizumab are well-established targeted drugs utilized in the treatment of solid tumors in clinical settings. They can exert anti-tumor effects by inhibiting PARP and tumor neovascularization. Advanced colorectal cancer (CRC) has a high degree of malignancy, and conventional surgical treatment and chemotherapy are effective. However, there is a pressing need to identify safe and effective treatments for patients with advanced CRC.

Research motivation

Olaparib combined with bevacizumab in the treatment of advanced CRC has an ideal clinical efficacy.

Research objectives

This study aims to investigate the short-term efficacy, time to progression, safety, and their effects on the serum parameters of olaparib combined with bevacizumab in advanced CRC treatment.

Research methods

Comparisons were made for the assessment of the short-term efficacy, time to progression (TTP), the incidence of adverse reactions, serum-related parameters [vascular endothelial growth factor (VEGF), matrix metalloprotein-9 (MMP-9), cyclooxygenase-2 (COX-2)], and tumor markers [human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199)] levels in patients with advanced CRC treated with classical FOLFOX chemotherapy and olaparib combined with bevacizumab chemotherapy.

Research results

The objective response rate and disease control rate in the observation group were significantly higher than those in the control group, and the median TTP in the observation group was better than that in the control group. After treatment, the serum levels of VEGF, MMP-9, COX-2, HE4, CA125, and CA199 in the observation group were lower than those in the control group, and the total incidence of adverse reactions in the observation group was also lower than that in the control group.

Research conclusions

Olaparib combined with bevacizumab in the treatment of advanced CRC has a remarkable clinical effect. Specifically, the combination can delay the disease and reduce serum VEGF, MMP-9, and COX-2 levels and tumor markers HE4, CA125, and CA199 levels, with a high degree of safety and reliability.

Research perspectives

The mechanism of olaparib combined with bevacizumab in the treatment of advanced CRC can be further investigated so as to enable a better understanding of its target and provide a comprehensive theoretical basis and data support for the clinical application of this treatment modality in patients with advanced CRC.